Two complementary reports described scalable approaches to discover molecular glues—small molecules that induce proximity between a target protein and ubiquitin ligases to trigger degradation. One study in Nature Chemical Biology outlined a high‑throughput ligand‑diversification platform that synthesizes and screens thousands of derivatives in cells to identify chemical inducers of proximity. Another feature traced the evolution from serendipitous finds to methodical discovery pipelines, highlighting how systematic chemistry and cellular assays accelerate identification of degrader molecules. Researchers focused on ENL in leukemia and other oncology targets, showing cell‑based functional screens can rapidly pinpoint selective degraders from vast chemical libraries. Authors and quoted lab leads emphasized that combining combinatorial chemistry, live‑cell degradation assays, and target‑engagement profiling reduces reliance on chance and opens new therapeutic options for previously “undruggable” proteins. These advances set the stage for industrializing molecular glue discovery, providing medicinal chemists and biologists with workflows to translate glue hits into lead degraders with potential clinical applications.